Literature DB >> 11337655

Revision myringoplasty with solvent-dehydrated human dura mater (Tutoplast).

S Yetişer1, F Tosun, B Satar.   

Abstract

OBJECTIVES: Several grafting materials have been used in the reconstruction of the perforations of the tympanic membrane. The use of dehydrated dura homografts as a substitute for the tympanic membrane has not been fully documented. On the other hand, revision surgery is more critical in terms of patients' expectations. The aim of this study is to determine the tissue stiffness, the compliance, and the wound healing rate of dura homografts in revision surgery of perforations of the tympanic membrane. STUDY DESIGN AND
SETTING: The charts of 45 patients who have received dura grafts because of re-perforation or failure of the myringoplasty have been reviewed retrospectively. The healing process of the myringoplasty, graft take rate, pure-tone hearing level, and tympanogram were reviewed. RESULTS AND
CONCLUSION: It has been concluded that dura homografts, which have excellent tissue-compatibility, stability, and an 86.7% graft success rate, are preferred in patients in whom their own temporalis fascia cannot be used because of previous operations. It has been demonstrated by tympanometric analysis that the compliance of the graft during various pressure applications is as good as the normal eardrum.

Entities:  

Mesh:

Year:  2001        PMID: 11337655     DOI: 10.1067/mhn.2001.115058

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  2 in total

1.  Are bovine pericardium underlay xenograft and butterfly inlay autograft efficient for transcanal tympanoplasty?

Authors:  Clotilde de Dorlodot; Gersende De Bie; Naima Deggouj; Monique Decat; Jean-Marc Gérard
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-12-13       Impact factor: 2.503

2.  The use of human dura mater as an interposition graft in the treatment of vesicovaginal fistula.

Authors:  Bülent Alagöl; Ali Serdar Gözen; Esat Kaya; Osman Inci
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.